06185.HK
CanSino Biologics, Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 25.78
−0.46%Year over year
Reported trailing growth
- Revenue
- +28.5%
- EBITDA
- +166.0%
- EBIT
- +69.9%
- EPS
- +120.8%
- Free cash flow
- +57.5%
- Operating cash flow
- -40.9%
Forward estimates
Based on analyst estimates
- Revenue
- -60.7%
- EBITDA
- +257.7%
- EPS
- +142.7%
Three-year CAGR
- Revenue
- +0.0%
- EBITDA
- +137.2%
- EBIT
- +69.9%
- Net income
- +107.2%
- EPS
- +107.2%
- Free cash flow
- +75.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026